PURCHASE, NY, January 31, 2007 -- Nutrition 21, Inc. (NASDAQ: NXXI) reported today that a peer reviewed analysis on chromium picolinate was published in the current edition of Diabetes Technology & Therapeutics. The analysis confirms that chromium picolinate is effective in improving glycemic control and normalizing lipid levels in people with type 2 diabetes.(1) The review, which analyzed research on chromium picolinate, supports the consistent beneficial effects of chromium picolinate and refutes a previous review that analyzed efficacy after combining results from all types of supplemental chromium.>>> Discuss This Story
